Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 7000 shares changing hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Down 50.0 %
The company has a debt-to-equity ratio of 138.88, a current ratio of 0.07 and a quick ratio of 0.46. The business’s 50 day moving average price is C$0.01 and its 200 day moving average price is C$0.02. The firm has a market cap of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Recommended Stories
- Five stocks we like better than Aequus Pharmaceuticals
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Micron: Why Now Is the Time to Be Brave
- Consumer Staples Stocks, Explained
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
